The United States Anti-Doping Agency (USADA) has suspended UFC light heavyweight Michal Oleksiejczuk for one-year after testing positive for the banned substance clomiphene in December. Clomiphene is an anti-estrogen agent.
Previously, Oleksiejczuk was already suspended by the Nevada Athletic Commission (NAC) for one-year and had his unanimous decision win over Khalil Rountree from UFC 219 in December overturned to a No Contest. Both those suspensions will continue to run concurrently.
His one-year ban retroactively began on December 30th of 2017 and he will be eligible for a return on December 30th of 2018. The 23-year-old is currently on a nine-fight win streak and is one of Europe’s brightest prospects.
Read USADA’s statement below:
“USADA announced today that Michał Oleksiejczuk, of Cyców, Poland, has accepted a one-year sanction for a violation of the UFC® Anti-Doping Policy after testing positive for a prohibited substance.
Oleksiejczuk, 23, tested positive for clomiphene following an in-competition urine test conducted on December 30, 2017, at UFC 219 in Las Vegas, Nev. Clomiphene is a Specified Substance in the category of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the WADA Prohibited List.
Oleksiejczuk’s one-year period of ineligibility began on December 30, 2017, the date his positive sample was collected, and is identical in length to the sanction imposed by the Nevada State Athletic Commission (NSAC) on March 13, 2018. In addition, the NSAC overturned Oleksiejczuk’s victory at UFC 219 to a no-contest.”